No Data
Announcement highlights | CHINA POWER's electricity sales volume increased by nearly 30% year-on-year in the first 11 months; WUXI APPTEC plans to sell its WuXi ATU Business in the USA and United Kingdom.
WUXI APPTEC plans to sell its WuXi ATU Business in the USA and United Kingdom; GF SEC's proprietary business can participate in carbon emission trading at legal trading venues within the territory.
Livzon Pharmaceutical Group Inc. (000513.SZ): Spent 5.4997 million yuan to repurchase 0.1457 million A-shares.
On December 25, Glonghui reported that Livzon Pharmaceutical Group Inc. (000513.SZ) announced the repurchase of 0.1457 million shares of its A-shares for the first time through centralized bidding on December 25, 2024, accounting for 0.02% of the company's total share capital. The highest purchase price was 37.97 yuan per share, and the lowest price was 37.50 yuan per share, with a total amount of funds used being 5.4997 million yuan (excluding transaction fees).
LIVZON PHARMA (01513.HK) spent 4.1397 million HKD to repurchase 0.1527 million shares on December 24.
According to a announcement on December 24 by LIVZON PHARMA (01513.HK), it spent 4.1397 million HKD to repurchase 0.1527 million shares on December 24, with a repurchase price per share ranging from 26.85 to 27.2 HKD.
LIVZON PHARMA (01513.HK) spent 5.66 million HKD to repurchase 0.211 million shares on December 23.
Gelonghui, December 23 - LIVZON PHARMA (01513.HK) announced that on December 23, it spent 5.66 million Hong Kong dollars to repurchase 0.211 million shares.
LIVZON PHARMA (01513.HK) spent 5.238 million Hong Kong dollars to buy back 0.195 million shares on December 20.
On December 20, Glonhui reported that LIVZON PHARMA (01513.HK) announced it repurchased 195,000 shares for HKD 5.238 million.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
No Data
